Indication
Neoadjuvant
6 clinical trials
5 products
Clinical trial
A Multicenter, Single-arm, Prospective Study of Neoadjuvant Pyrotinib Combined With Trastuzumab，Carboplatin and Paclitaxel for ER+/HER2+ Early or Locally Advanced Breast CancerStatus: Recruiting, Estimated PCD: 2025-05-11
Product
PyrotinibClinical trial
An Exploration of Candidates for Neoadjuvant Treatment in Resectable Pancreatic Cancer According to Tumor-vessel Relationship and CA 19-9 LevelsStatus: Completed, Estimated PCD: 2021-12-01
Product
Neoadjuvant treatmentClinical trial
Phase II, Single-arm Clinical Trial Evaluating Efficacy and Safety of Pembrolizumab in Combination With a Soluble LAG-3 Protein, Eftilagimod Alpha, and Radiotherapy in Neoadjuvant Treatment of Patients With Soft Tissue Sarcomas (EFTISARC-NEO)Status: Recruiting, Estimated PCD: 2025-04-30
Product
PembrolizumabClinical trial
Pembrolizumab Plus Albumin Paclitaxel or 5-fluorouracil and Cisplatin Versus 5-fluorouracil and Cisplatin in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma: a Prospective, Randomized Controlled Trial StudyStatus: Recruiting, Estimated PCD: 2031-12-31
Clinical trial
A Phase 2 Clinical Trial of Neoadjuvant Camrelizumab Plus Apatinib and Temozolomide in High Risk Clinical Stage Ⅱ-Ⅲ Acral MelanomaStatus: Recruiting, Estimated PCD: 2024-12-31
Product
CamrelizumabClinical trial
A Multicenter Randomized Controlled Clinical Study of Neoadjuvant Combination of Axitinib Plus PD-1 Monoclonal Antibody to Improve Disease Free Survival of Patients With Renal Cell CarcinomaStatus: Recruiting, Estimated PCD: 2025-07-16
Product
Axitinib plus Toripalimab